Bioventix PLC (LON:BVXP) Insider Bruce Hiscock Buys 31 Shares

Bioventix PLC (LON:BVXP - Get Free Report) insider Bruce Hiscock purchased 31 shares of the business's stock in a transaction that occurred on Monday, April 28th. The stock was acquired at an average price of GBX 2,632 ($34.93) per share, for a total transaction of £815.92 ($1,082.98).

Bioventix Stock Down 0.3 %

Shares of Bioventix stock traded down GBX 8 ($0.11) during trading hours on Friday, hitting GBX 2,692 ($35.73). The company's stock had a trading volume of 22,728 shares, compared to its average volume of 8,293. The business has a fifty day moving average of GBX 2,633.46 and a 200 day moving average of GBX 3,115.76. Bioventix PLC has a 1-year low of GBX 2,200 ($29.20) and a 1-year high of GBX 4,550 ($60.39). The company has a market capitalization of £140.96 million, a PE ratio of 17.41 and a beta of 0.35.

Bioventix (LON:BVXP - Get Free Report) last announced its quarterly earnings results on Monday, March 31st. The biotechnology company reported GBX 72.27 ($0.96) earnings per share (EPS) for the quarter. Bioventix had a return on equity of 69.09% and a net margin of 59.51%. On average, sell-side analysts anticipate that Bioventix PLC will post 166.3066955 earnings per share for the current fiscal year.

Bioventix Cuts Dividend

The business also recently announced a dividend, which was paid on Friday, April 25th. Investors of record on Thursday, April 10th were issued a dividend of GBX 70 ($0.93) per share. The ex-dividend date was Thursday, April 10th. This represents a dividend yield of 2.95%. Bioventix's payout ratio is currently 102.19%.

Bioventix Company Profile

Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; and Pyrene (HOP-G) ELISA kit to monitor human exposure to industrial pollutants.